Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2003 2
2005 1
2012 1
2013 1
2014 2
2018 1
2019 4
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia.
Tadmor T, Levy I, Herishanu Y, Goldschmidt N, Bairey O, Yuklea M, Shvidel L, Fineman R, Aviv A, Ruchlemer R, Braester A, Dally N, Rouvio O, Shaulov A, Greenbaum U, Inbar M, Polliack A. Tadmor T, et al. Among authors: yuklea m. Leuk Res. 2019 Jul;82:24-28. doi: 10.1016/j.leukres.2019.05.006. Epub 2019 May 19. Leuk Res. 2019. PMID: 31152919
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y, Tadmor T, Braester A, Bairey O, Aviv A, Rahimi-Levene N, Fineman R, Levi I, Yuklea M, Ruchlemer R, Shvidel L, Polliack A. Herishanu Y, et al. Among authors: yuklea m. Hematol Oncol. 2019 Apr;37(2):185-192. doi: 10.1002/hon.2580. Epub 2019 Mar 12. Hematol Oncol. 2019. PMID: 30756414 Clinical Trial.
A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain.
Tadmor T, Braester A, Najib D, Aviv A, Herishanu Y, Yuklea M, Shvidel L, Rahimi-Levene N, Ruchlemer R, Arad A, Fogl C, Henig C, Barak M, Magal L, Polliack A, Townsend K; Israeli CLL study group. Tadmor T, et al. Among authors: yuklea m. Eur J Haematol. 2019 Oct;103(4):335-341. doi: 10.1111/ejh.13288. Epub 2019 Jul 26. Eur J Haematol. 2019. PMID: 31278876
Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group.
Tadmor T, Shvidel L, Bairey O, Goldschmidt N, Ruchlemer R, Fineman R, Rahimi-Levene N, Herishanu Y, Yuklea M, Arad A, Aviv A, Polliack A; Israeli CLL Study Group. Tadmor T, et al. Among authors: yuklea m. Am J Hematol. 2014 Nov;89(11):E218-22. doi: 10.1002/ajh.23826. Epub 2014 Sep 2. Am J Hematol. 2014. PMID: 25110869 Free article.
Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications.
Tadmor T, Shvidel L, Aviv A, Ruchlemer R, Bairey O, Yuklea M, Herishanu Y, Braester A, Rahimi-Levene N, Vernea F, Ben-Ezra J, Bejar J, Polliack A; Israeli CLL Study Group. Tadmor T, et al. Among authors: yuklea m. Cancer. 2013 May 15;119(10):1853-9. doi: 10.1002/cncr.27930. Epub 2013 Feb 19. Cancer. 2013. PMID: 23423815 Free article.
Insect-bite-like reaction in patients with chronic lymphocytic leukemia: a study from the Israeli Chronic Lymphocytic Leukemia Study Group.
Bairey O, Goldschmidt N, Ruchlemer R, Tadmor T, Rahimi-Levene N, Yuklea M, Shvidel L, Berrebi A, Polliack A, Herishanu Y; Israeli Chronic Lymphocytic Leukemia Study Group (ICLLSG). Bairey O, et al. Among authors: yuklea m. Eur J Haematol. 2012 Dec;89(6):491-6. doi: 10.1111/ejh.12015. Epub 2012 Oct 26. Eur J Haematol. 2012. PMID: 23033927
13 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page